Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., … Fuster, V. (2020). Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. Journal of the American College of Cardiology, 76(25), 2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010

Goldsborough E, Osuji N, Blaha MJ (2022) Assessment of Cardiovascular Disease Risk: A 2022 Update. Endocrinol Metab Clin North Am 51:483–509. https://doi.org/10.1016/J.ECL.2022.02.005 - Search Results - PMC. (n.d.). PubMed Central (PMC). Retrieved February 23, 2026, from https://pmc.ncbi.nlm.nih.gov/search/search/?term=Goldsborough+E%2 C+Osuji+N%2 C+Blaha+MJ+%282022%29+Assessment+of+Cardiovascular+Disease+Risk%3A+A+2022+Update.+Endocrinol+Metab+Clin+North+Am+51%3A483%E2%80%93509.+https%3A%2F%2Fdoi.org%2F10.1016%2FJ.ECL.2022.02.005+

Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., … Martin, S. S. (2022). Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation, 145(8), e153–e639. https://doi.org/10.1161/CIR.0000000000001052

Sheibani, M., Azizi, Y., Shayan, M., Nezamoleslami, S., Eslami, F., Farjoo, M. H., & Dehpour, A. R. (2022). Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches. Cardiovascular Toxicology, 22(4), 292–310. https://doi.org/10.1007/s12012-022-09721-1

Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 139, 111708. https://doi.org/10.1016/j.biopha.2021.111708

Prathumsap, N., Shinlapawittayatorn, K., Chattipakorn, S. C., & Chattipakorn, N. (2020). Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies. European Journal of Pharmacology, 866, 172818. https://doi.org/10.1016/j.ejphar.2019.172818

Cappetta, D., Rossi, F., Piegari, E., Quaini, F., Berrino, L., Urbanek, K., & De Angelis, A. (2018). Doxorubicin targets multiple players: A new view of an old problem. Pharmacological Research, 127, 4–14. https://doi.org/10.1016/j.phrs.2017.03.016

Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway - PubMed. (n.d.). Retrieved February 23, 2026, from https://pubmed.ncbi.nlm.nih.gov/31998130/

Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management - PubMed. (n.d.). Retrieved February 23, 2026, from https://pubmed.ncbi.nlm.nih.gov/34243633/

Henriksen, P. A. (2018). Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart, 104(12), 971–977. https://doi.org/10.1136/heartjnl-2017-312103

Li, K., Chen, W., Ma, L., Yan, L., & Wang, B. (2024). Approaches for reducing chemo/radiation-induced cardiotoxicity by nanoparticles. Environmental Research, 244, 117264. https://doi.org/10.1016/j.envres.2023.117264

PubChem. (n.d.). Doxorubicin. Retrieved February 23, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/31703

Mordente, A., Meucci, E., Martorana, G. E., Tavian, D., & Silvestrini, A. (2017). Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity. Current Medicinal Chemistry, 24(15), 1607–1626. https://doi.org/10.2174/0929867323666161214120355

Martins-Teixeira, M. B., & Carvalho, I. (2020). Antitumour Anthracyclines: Progress and Perspectives. ChemMedChem, 15(11), 933–948. https://doi.org/10.1002/cmdc.202000131

Corremans, R., Adão, R., De Keulenaer, G. W., Leite-Moreira, A. F., & Brás-Silva, C. (2019). Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Clinical and Experimental Pharmacology & Physiology, 46(3), 204–215. https://doi.org/10.1111/1440-1681.13036

Qiao, X., van der Zanden, S. Y., Wander, D. P. A., Borràs, D. M., Song, J.-Y., Li, X., … Neefjes, J. (2020). Uncoupling DNA damage from chromatin damage to detoxify doxorubicin. Proceedings of the National Academy of Sciences of the United States of America, 117(26), 15182–15192. https://doi.org/10.1073/pnas.1922072117

Belger, C., Abrahams, C., Imamdin, A., & Lecour, S. (2023). Doxorubicin-induced cardiotoxicity and risk factors. International Journal of Cardiology. Heart & Vasculature, 50, 101332. https://doi.org/10.1016/j.ijcha.2023.101332

Tyler, L. S., Cole, S. W., May, J. R., Millares, M., Valentino, M. A., Vermeulen, L. C., … ASHP Expert Panel on Formulary Management. (2008). ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists, 65(13), 1272–1283. https://doi.org/10.2146/ajhp080086

Shi, S., Chen, Y., Luo, Z., Nie, G., & Dai, Y. (2023). Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. Cell communication and signaling: CCS, 21(1), 61. https://doi.org/10.1186/s12964-023-01077-5

Myers, A. L., Kawedia, J. D., Champlin, R. E., Kramer, M. A., Nieto, Y., Ghose, R., & Andersson, B. S. (2017). Clarifying Busulfan Metabolism and Drug Interactions to Support New Therapeutic Drug Monitoring Strategies: A Comprehensive Review. Expert opinion on drug metabolism & toxicology, 13(9), 901–923. https://doi.org/10.1080/17425255.2017.1360277

Sinha, S. J., Kumar, B., Prasad, C. P., Chauhan, S. S., & Kumar, M. (2025). Emerging Research and Future Directions on Doxorubicin: A Snapshot. Asian Pacific Journal of Cancer Prevention : APJCP, 26(1), 5–15. https://doi.org/10.31557/APJCP.2025.26.1.5

Atwal, M., Swan, R. L., Rowe, C., Lee, K. C., Lee, D. C., Armstrong, L., … Austin, C. A. (2019). Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations. Molecular Pharmacology, 96(4), 475–484. https://doi.org/10.1124/mol.119.117259

Double-strand DNA break repair: molecular mechanisms and therapeutic targets - PMC. (n.d.). Retrieved February 23, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC10556206/

Ito-Hagiwara, K., Hagiwara, J., Endo, Y., Becker, L. B., & Hayashida, K. (2025). Cardioprotective strategies against doxorubicin-induced cardiotoxicity: A review from standard therapies to emerging mitochondrial transplantation. Biomedicine & Pharmacotherapy, 189, 118315. https://doi.org/10.1016/j.biopha.2025.118315

Ciappina, G., Colarusso, L., Maiorana, E., Ottaiano, A., Franchina, T., Picone, A., … Berretta, M. (2025). Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice. Pharmaceuticals, 18(9), 1399. https://doi.org/10.3390/ph18091399

Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association | Circulation. (n.d.). Retrieved February 23, 2026, from https://www.ahajournals.org/doi/10.1161/CIR.0000000000001308

Quagliariello, V., Berretta, M., Maurea, F., Barbato, M., Paccone, A., Iovine, M., … Maurea, N. (2025). Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative Review. Healthcare, 13(20), 2599. https://doi.org/10.3390/healthcare13202599

Nur Azan, N. I., Abdul Karim, N., Sulaiman, N., Ng, M. H., Najib, A. M., Hassan, H., & Alias, E. (2026). Oxidative Stress and Mitochondrial Dysfunction in Cardiovascular Aging: Current Insights and Therapeutic Advances. Biomedicines, 14(1), 100. https://doi.org/10.3390/biomedicines14010100

Huang, X., Chen, Y., Zhang, Y., Hu, X., Yang, W., Pan, T., … Li, L. (2026). Pterostilbene alleviates doxorubicin-induced cardiotoxicity by inhibiting cardiomyocytes pyroptosis mediated by the IL-6/STAT3-caspase-3/GSDME axis and M1 polarization of macrophages. Pharmacological Research, 225, 108129. https://doi.org/10.1016/j.phrs.2026.108129

Vitale, R., Marzocco, S., & Popolo, A. (2024). Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account. International Journal of Molecular Sciences, 25(13), 7477. https://doi.org/10.3390/ijms25137477

Different Mechanisms in Doxorubicin-Induced Neurotoxicity: Impact of BRCA Mutations | MDPI. (n.d.). Retrieved February 24, 2026, from https://www.mdpi.com/1422-0067/26/10/4736

Mitochondrial Oxidative Stress—A Causative Factor and Therapeutic Target in Many Diseases - PMC. (n.d.). Retrieved February 24, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC8707347/

Carraro, M., & Bernardi, P. (2023). The mitochondrial permeability transition pore in Ca2 + homeostasis. Cell Calcium, 111, 102719. https://doi.org/10.1016/j.ceca.2023.102719

Bellanti, F., Coda, A. R. D., Trecca, M. I., Lo Buglio, A., Serviddio, G., & Vendemiale, G. (2025). Redox Imbalance in Inflammation: The Interplay of Oxidative and Reductive Stress. Antioxidants, 14(6), 656. https://doi.org/10.3390/antiox14060656

Lai, C., Shi, X., Li, L., Cheng, M., Liu, X., Liu, S., … An, N. (2021). Enhancing iron redox cycling for promoting heterogeneous Fenton performance: A review. Science of The Total Environment, 775, 145850. https://doi.org/10.1016/j.scitotenv.2021.145850

Cardiac PTN-SIRT1 axis alleviates oxidative stress and promotes mitochondrial energy reprogramming to mitigate doxorubicin-induced cardiotoxicity through AMPK/PGC1α signaling: PTN mitigates doxorubicin-induced cardiotoxicity - PMC. (n.d.). Retrieved February 24, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC12900733/

Review Reports - Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account. (n.d.). MDPI. Retrieved February 24, 2026, from https://www.mdpi.com

Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R., & Abel, E. D. (2021). Cardiac Energy Metabolism in Heart Failure. Circulation Research, 128(10), 1487–1513. https://doi.org/10.1161/CIRCRESAHA.121.318241

Schirone, L., D’Ambrosio, L., Forte, M., Genovese, R., Schiavon, S., Spinosa, G., … Sciarretta, S. (2022). Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay. Cells, 11(13), 2000. https://doi.org/10.3390/cells11132000

Ling, G., Wang, X., Tan, N., Cao, J., Li, W., Zhang, Y., … Wang, Y. (2022). Mechanisms and Drug Intervention for Doxorubicin-Induced Cardiotoxicity Based on Mitochondrial Bioenergetics. Oxidative Medicine and Cellular Longevity, 2022, 7176282. https://doi.org/10.1155/2022/7176282

Dhingra, R., Guberman, M., Rabinovich-Nikitin, I., Gerstein, J., Margulets, V., Gang, H., … Kirshenbaum, L. A. (2020). Impaired NF-κB signalling underlies cyclophilin D-mediated mitochondrial permeability transition pore opening in doxorubicin cardiomyopathy. Cardiovascular Research, 116(6), 1161–1174. https://doi.org/10.1093/cvr/cvz240

Wu, B. B., Leung, K. T., & Poon, E. N.-Y. (2022). Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity. International Journal of Molecular Sciences, 23(3), 1912. https://doi.org/10.3390/ijms23031912

Zeng, C., Duan, F., Hu, J., Luo, B., Huang, B., Lou, X., … Tan, H. (2020). NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox Biology, 34, 101523. https://doi.org/10.1016/j.redox.2020.101523

Mfn2-mediated mitochondrial fusion alleviates doxorubicin-induced cardiotoxicity with enhancing its anticancer activity through metabolic switch - PubMed. (n.d.). Retrieved February 24, 2026, from https://pubmed.ncbi.nlm.nih.gov/35413642/

Shinlapawittayatorn, K., Chattipakorn, S. C., & Chattipakorn, N. (2022). The effects of doxorubicin on cardiac calcium homeostasis and contractile function. Journal of Cardiology, 80(2), 125–132. https://doi.org/10.1016/j.jjcc.2022.01.001

Nordgren, K. K. S., Hampton, M., & Wallace, K. B. (2017). Editor’s Highlight: The Altered DNA Methylome of Chronic Doxorubicin Exposure in Sprague Dawley Rats. Toxicological Sciences: An Official Journal of the Society of Toxicology, 159(2), 470–479. https://doi.org/10.1093/toxsci/kfx150

Robichaux, D. J., Harata, M., Murphy, E., & Karch, J. (2023). Mitochondrial permeability transition pore-dependent necrosis. Journal of Molecular and Cellular Cardiology, 174, 47–55. https://doi.org/10.1016/j.yjmcc.2022.11.003

Strubbe-Rivera, J. O., Chen, J., West, B. A., Parent, K. N., Wei, G.-W., & Bazil, J. N. (2021). Modeling the Effects of Calcium Overload on Mitochondrial Ultrastructural Remodeling. Applied Sciences, 11(5), 2071. https://doi.org/10.3390/app11052071

Walkon, L. L., Strubbe-Rivera, J. O., & Bazil, J. N. (2022). Calcium Overload and Mitochondrial Metabolism. Biomolecules, 12(12), 1891. https://doi.org/10.3390/biom12121891

Kitakata, H., Endo, J., Ikura, H., Moriyama, H., Shirakawa, K., Katsumata, Y., & Sano, M. (2022). Therapeutic Targets for DOX-Induced Cardiomyopathy: Role of Apoptosis vs. Ferroptosis. International Journal of Molecular Sciences, 23(3), 1414. https://doi.org/10.3390/ijms23031414

Jiang, Q., Chen, X., Tian, X., Zhang, J., Xue, S., Jiang, Y., … Wang, Q. (2022). Tanshinone I inhibits doxorubicin-induced cardiotoxicity by regulating Nrf2 signaling pathway. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 106, 154439. https://doi.org/10.1016/j.phymed.2022.154439

Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity - PubMed. (n.d.). Retrieved February 24, 2026, from https://pubmed.ncbi.nlm.nih.gov/30728290/

Ye, X., Li, Y., Lv, B., Qiu, B., Zhang, S., Peng, H., … Jin, H. (2022). Endogenous Hydrogen Sulfide Persulfidates Caspase-3 at Cysteine 163 to Inhibit Doxorubicin-Induced Cardiomyocyte Apoptosis. Oxidative Medicine and Cellular Longevity, 2022, 6153772. https://doi.org/10.1155/2022/6153772

miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation - PubMed. (n.d.). Retrieved February 24, 2026, from https://pubmed.ncbi.nlm.nih.gov/26160071/

Bartlett, J. J., Trivedi, P. C., Yeung, P., Kienesberger, P. C., & Pulinilkunnil, T. (2016). Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy. The Biochemical Journal, 473(21), 3769–3789. https://doi.org/10.1042/BCJ20160385

Koleini, N., & Kardami, E. (2017). Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget, 8(28), 46663–46680. https://doi.org/10.18632/oncotarget.16944

Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update - PMC. (n.d.). Retrieved February 24, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC12193598/

Niu, Y., Wang, L., Zhang, Y., Zou, Y., & Zhou, C. (2025). Pyroptosis in cardiovascular diseases: roles, mechanisms, and clinical implications. Frontiers in Cardiovascular Medicine, 12, 1629016. https://doi.org/10.3389/fcvm.2025.1629016

Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy - PMC. (n.d.). Retrieved February 24, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC7121924/

Epigenetic Regulation of Aging and its Rejuvenation - PMC. (n.d.). Retrieved February 24, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC12402629/

Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways - PMC. (n.d.). Retrieved February 24, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC11072696/

Bosman, M., Krüger, D. N., Favere, K., Wesley, C. D., Neutel, C. H. G., Van Asbroeck, B., … Guns, P.-J. D. F. (2021). Doxorubicin Impairs Smooth Muscle Cell Contraction: Novel Insights in Vascular Toxicity. International Journal of Molecular Sciences, 22(23), 12812. https://doi.org/10.3390/ijms222312812

Sheibani, M., Azizi, Y., Shayan, M., Nezamoleslami, S., Eslami, F., Farjoo, M. H., & Dehpour, A. R. (2022). Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches. Cardiovascular Toxicology, 22(4), 292–310. https://doi.org/10.1007/s12012-022-09721-1

Xu, A., Deng, F., Chen, Y., Kong, Y., Pan, L., Liao, Q., … Sheng, X. (2020). NF-κB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 130, 110525. https://doi.org/10.1016/j.biopha.2020.110525

Aziz, A. U. R., Geng, C., Li, W., Yu, X., Qin, K.-R., Wang, H., & Liu, B. (2019). Doxorubicin Induces ER Calcium Release via Src in Rat Ovarian Follicles. Toxicological Sciences: An Official Journal of the Society of Toxicology, 168(1), 171–178. https://doi.org/10.1093/toxsci/kfy284

Ge, W., Yuan, M., Ceylan, A. F., Wang, X., & Ren, J. (2016). Mitochondrial aldehyde dehydrogenase protects against doxorubicin cardiotoxicity through a transient receptor potential channel vanilloid 1-mediated mechanism. Biochimica Et Biophysica Acta, 1862(4), 622–634. https://doi.org/10.1016/j.bbadis.2015.12.014

Sun, J., Zhou, J., Sun, S., Lin, H., Zhang, H., Zhong, Z., … Guo, H. (2023). Protective effect of urotensin II receptor antagonist urantide and exercise training on doxorubicin-induced cardiotoxicity. Scientific Reports, 13(1), 1279. https://doi.org/10.1038/s41598-023-28437-y

Grakova, E. V., Shilov, S. N., Kopeva, K. V., Berezikova, E. N., Popova, A. A., Neupokoeva, M. N., … Teplyakov, A. T. (2021). Anthracycline-Induced Cardiotoxicity: The Role of Endothelial Dysfunction. Cardiology, 146(3), 315–323. https://doi.org/10.1159/000512771

Podyacheva, E., Danilchuk, M., & Toropova, Y. (2023). Molecular mechanisms of endothelial remodeling under doxorubicin treatment. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 162, 114576. https://doi.org/10.1016/j.biopha.2023.114576

Arrigoni, R., Jirillo, E., & Caiati, C. (2025). Pathophysiology of Doxorubicin-Mediated Cardiotoxicity. Toxics, 13(4), 277. https://doi.org/10.3390/toxics13040277

Pan, J.-A., Zhang, H., Lin, H., Gao, L., Zhang, H.-L., Zhang, J.-F., … Gu, J. (2021). Irisin ameliorates doxorubicin-induced cardiac perivascular fibrosis through inhibiting endothelial-to-mesenchymal transition by regulating ROS accumulation and autophagy disorder in endothelial cells. Redox Biology, 46, 102120. https://doi.org/10.1016/j.redox.2021.102120

Algieri, C., Bernardini, C., Oppedisano, F., La Mantia, D., Trombetti, F., Palma, E., … Nesci, S. (2022). The Impairment of Cell Metabolism by Cardiovascular Toxicity of Doxorubicin Is Reversed by Bergamot Polyphenolic Fraction Treatment in Endothelial Cells. International Journal of Molecular Sciences, 23(16), 8977. https://doi.org/10.3390/ijms23168977

Luu, A. Z., Chowdhury, B., Al-Omran, M., Teoh, H., Hess, D. A., & Verma, S. (2018). Role of Endothelium in Doxorubicin-Induced Cardiomyopathy. JACC. Basic to translational science, 3(6), 861–870. https://doi.org/10.1016/j.jacbts.2018.06.005

Al-Kuraishy, H. M., Al-Hussaniy, H. A., Al-Gareeb, A. I., Negm, W. A., El-Kadem, A. H., Batiha, G. E.-S., … Conte-Junior, C. A. (2022). Combination of Panax ginseng C. A. Mey and Febuxostat Boasted Cardioprotective Effects Against Doxorubicin-Induced Acute Cardiotoxicity in Rats. Frontiers in Pharmacology, 13, 905828. https://doi.org/10.3389/fphar.2022.905828

Karamitsos, T. D., Arvanitaki, A., Karvounis, H., Neubauer, S., & Ferreira, V. M. (2020). Myocardial Tissue Characterization and Fibrosis by Imaging. JACC. Cardiovascular imaging, 13(5), 1221–1234. https://doi.org/10.1016/j.jcmg.2019.06.030

Silva, A. C., Pereira, C., Fonseca, A. C. R. G., Pinto-do-Ó, P., & Nascimento, D. S. (2020). Bearing My Heart: The Role of Extracellular Matrix on Cardiac Development, Homeostasis, and Injury Response. Frontiers in Cell and Developmental Biology, 8, 621644. https://doi.org/10.3389/fcell.2020.621644

Prathumsap, N., Shinlapawittayatorn, K., Chattipakorn, S. C., & Chattipakorn, N. (2020). Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies. European Journal of Pharmacology, 866, 172818. https://doi.org/10.1016/j.ejphar.2019.172818

Fu, X., Tang, J., Wen, P., Huang, Z., & Najafi, M. (2021). Redox interactions-induced cardiac toxicity in cancer therapy. Archives of Biochemistry and Biophysics, 708, 108952. https://doi.org/10.1016/j.abb.2021.108952

Chen, M. S., Lee, R. T., & Garbern, J. C. (2022). Senescence mechanisms and targets in the heart. Cardiovascular Research, 118(5), 1173–1187. https://doi.org/10.1093/cvr/cvab161

Panpan, T., Yuchen, D., Xianyong, S., Meng, L., Ruijuan, H., Ranran, D., … Rongrong, X. (2022). Cardiac Remodelling Following Cancer Therapy: A Review. Cardiovascular Toxicology, 22(9), 771–786. https://doi.org/10.1007/s12012-022-09762-6

Khawaja, A., & Bromage, D. I. (2021). The innate immune response in myocarditis. The International Journal of Biochemistry & Cell Biology, 134, 105973. https://doi.org/10.1016/j.biocel.2021.105973

Trapani, D., Zagami, P., Nicolò, E., Pravettoni, G., & Curigliano, G. (2020). Management of Cardiac Toxicity Induced by Chemotherapy. Journal of Clinical Medicine, 9(9), 2885. https://doi.org/10.3390/jcm9092885

Kawada, J.-I., Takeuchi, S., Imai, H., Okumura, T., Horiba, K., Suzuki, T., … Ito, Y. (2021). Immune cell infiltration landscapes in pediatric acute myocarditis analyzed by CIBERSORT. Journal of Cardiology, 77(2), 174–178. https://doi.org/10.1016/j.jjcc.2020.08.004

Lafuse, W. P., Wozniak, D. J., & Rajaram, M. V. S. (2020). Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair. Cells, 10(1), 51. https://doi.org/10.3390/cells10010051

Borgers, J. S. W., van Schijndel, A. W., van Thienen, J. V., Klobuch, S., Seijkens, T. T. P., Tobin, R. P., … Haanen, J. B. a. G. (2024). Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned. ESMO open, 9(2), 102383. https://doi.org/10.1016/j.esmoop.2024.102383

Luo, X., Wang, R., Zhang, X., Wen, X., Deng, S., & Xie, W. (2023). Identification CCL2,CXCR2,S100A9 of the immune-related gene markers and immune infiltration characteristics of inflammatory bowel disease and heart failure via bioinformatics analysis and machine learning. Frontiers in Cardiovascular Medicine, 10, 1268675. https://doi.org/10.3389/fcvm.2023.1268675

Rolski, F., & Błyszczuk, P. (2020). Complexity of TNF-α Signaling in Heart Disease. Journal of Clinical Medicine, 9(10), 3267. https://doi.org/10.3390/jcm9103267

Adamo, L., Rocha-Resende, C., Prabhu, S. D., & Mann, D. L. (2020). Reappraising the role of inflammation in heart failure. Nature Reviews. Cardiology, 17(5), 269–285. https://doi.org/10.1038/s41569-019-0315-x

Chen, D.-S., Yan, J., & Yang, P.-Z. (2022). Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity. Frontiers in Cardiovascular Medicine, 9, 812578. https://doi.org/10.3389/fcvm.2022.812578

Willis, M. S., Parry, T. L., Brown, D. I., Mota, R. I., Huang, W., Beak, J. Y., … Jensen, B. C. (2019). Doxorubicin Exposure Causes Subacute Cardiac Atrophy Dependent on the Striated Muscle-Specific Ubiquitin Ligase MuRF1. Circulation. Heart Failure, 12(3), e005234. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005234

Xia, P., Chen, J., Liu, Y., Fletcher, M., Jensen, B. C., & Cheng, Z. (2020). Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1. The Journal of Biological Chemistry, 295(13), 4265–4276. https://doi.org/10.1074/jbc.RA119.011571

Shimauchi, T., Numaga-Tomita, T., Ito, T., Nishimura, A., Matsukane, R., Oda, S., … Nishida, M. (2017). TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy. JCI insight, 2(15), e93358, 93358. https://doi.org/10.1172/jci.insight.93358

Li, Z., Xing, J., Ma, X., Zhang, W., Wang, C., Wang, Y., … Tang, H. (2024). An orally administered bacterial membrane protein nanodrug ameliorates doxorubicin cardiotoxicity through alleviating impaired intestinal barrier. Bioactive Materials, 37, 517–532. https://doi.org/10.1016/j.bioactmat.2024.03.027

Xu, J., Pi, J., Zhang, Y., Zhou, J., Zhang, S., & Wu, S. (2023). Effects of Ferroptosis on Cardiovascular Diseases. Mediators of Inflammation, 2023, 6653202. https://doi.org/10.1155/2023/6653202

Yan, F., Li, K., Xing, W., Dong, M., Yi, M., & Zhang, H. (2022). Role of Iron-Related Oxidative Stress and Mitochondrial Dysfunction in Cardiovascular Diseases. Oxidative Medicine and Cellular Longevity, 2022, 5124553. https://doi.org/10.1155/2022/5124553

Hu, Z. (2024). Exploring the mechanism of curcumin in the treatment of doxorubicin-induced cardiotoxicity based on network pharmacology and molecular docking technology. Medicine, 103(7), e36593. https://doi.org/10.1097/MD.0000000000036593

Ahmadi, M., Hedayatizadeh-Omran, A., Alizadeh-Navaei, R., Saeedi, M., Zaboli, E., Amjadi, O., … Besharat, Z. (2022). Effects of Vitamin E on Doxorubicin Cytotoxicity in Human Breast Cancer Cells in Vitro. Asian Pacific journal of cancer prevention: APJCP, 23(1), 201–205. https://doi.org/10.31557/APJCP.2022.23.1.201

Melatonin mitigates oxidative damage induced by anthracycline: a systematic-review and meta-analysis of murine models - PubMed. (n.d.). Retrieved February 25, 2026, from https://pubmed.ncbi.nlm.nih.gov/38075951/

The Challenges of Predicting Drug-Induced QTc Prolongation in Humans - PMC. (n.d.). Retrieved February 25, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC9041548/

Zheng, H., & Zhan, H. (2025). Dexrazoxane makes doxorubicin-induced heart failure a rare event in sarcoma patients receiving high cumulative doses. Cardio-oncology, 11, 29. https://doi.org/10.1186/s40959-025-00323-8

Goje, I.-D., Goje, G.-I., Ordodi, V. L., Ciobotaru, V. G., Ivan, V. S., Buzaș, R., … Lighezan, D.-F. (2025). Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology. Pharmaceuticals, 18(5). https://doi.org/10.3390/ph18050681

Dai, B., Wang, F., Nie, X., Du, H., Zhao, Y., Yin, Z., … Chen, C. (2020). The Cell Type-Specific Functions of miR-21 in Cardiovascular Diseases. Frontiers in Genetics, 11, 563166. https://doi.org/10.3389/fgene.2020.563166

Liu, L.-P., Zhang, X.-L., & Li, J. (2021). New perspectives on angiotensin-converting enzyme 2 and its related diseases. World Journal of Diabetes, 12(6), 839–854. https://doi.org/10.4239/wjd.v12.i6.839

Hwang, H.-J., & Lee, T.-G. (2023). Impact on clinical outcomes of renin-angiotensin system inhibitors against doxorubicin-related toxicity in patients with breast cancer and hypertension: A nationwide cohort study in South Korea. PloS One, 18(11), e0294649. https://doi.org/10.1371/journal.pone.0294649

Gao, Y., Wang, R., Jiang, J., Hu, Y., Li, H., & Wang, Y. (2023). ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agent